Award
National Cancer Institute 1R42CA287679-01
Clinical testing of Listeria-TT and Gemcitabine in a Phase I clinical trial with PDAC patients
Recipient
Loki Therapeutics, Inc
Award Amount
$294,962.00
Ceiling
$294,962.00
Awarded
May 29, 2024
Identifier
1R42CA287679-01
NIH/NCI awarded approximately $294,962 for a Phase I clinical trial testing Listeria-TT and Gemcitabine in PDAC patients, starting June 2024 and ending December 2026.
Description
A Phase I clinical trial for a novel immunotherapeutic approach using Listeria-TT and Gemcitabine for unresectable PDAC. The project involves manufacturing GMP-grade Listeria-TT+GEM, establishing pathology and toxicology profiles, and conducting a clinical trial. The project has received positive feedback from the FDA and has licensed patents for the therapy.